This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Pfizer's Second Biosimilar of Remicade Receives FDA Approval
by Zacks Equity Research
The FDA approves Ixifi, Pfizer's (PFE) second biosimilar version of Johnson & Johnson's rheumatoid arthritis drug, Remicade. Ixifi receives the nod for all approved indications of Remicade.
Roche/AbbVie Report Positive Phase III Results on Venclexta
by Zacks Equity Research
Roche (RHHBY) announced positive results from a pivotal phase III study, MURANO, evaluating Venclexta plus Rituxan compared to bendamustine plus Rituxan (BR) for the treatment of relapsed or refractory chronic lymphocytic leukemia (CLL).
Bristol-Myers (BMY) Reports Positive Data on Leukemia Drug
by Zacks Equity Research
Bristol-Myers Squibb Company (BMY) announced positive data from an ongoing phase II study on leukemia drug Sprycel in addition to a chemotherapy regimen modelled on a Berlin-Frankfurt-Munster high-risk backbone for two years.
Novartis Announces Positive Data on Sickle Cell Disease Drug
by Zacks Equity Research
Novartis (NVS) announced positive data from a phase II study, SUSTAIN, on pipeline candidate crizanlizumab which deferred the time to first sickle cell pain crisis (SCPC) in patients compared to placebo in key subgroups of adult patients with sickle cell.
AbbVie/J&J's Imbruvica Succeeds in Combo Study with Rituxan
by Zacks Equity Research
AbbVie (ABBV) J&J's combination study evaluating Imbruvica in Waldenstrom's macroglobulinemia (WM), a rare form of non-Hodgkin's lymphoma, meets primary endpoint.
Biotech Stock Roundup: FDA Nod for Amgen PCSK9 Inhibitor, Revance Up on RT002 Data
by Arpita Dutt
Data presentations and regulatory updates were the key highlights this week with companies like AbbVie (ABBV) and Clovis providing data on their pipeline candidates.
AbbVie Psoriasis Candidate Succeeds in 4th Phase III Study
by Zacks Equity Research
AbbVie (ABBV) announces data from a phase III study on risankizumab, which shows that a significant portion of plaque psoriasis patients treated with risankizumab achieved high levels of skin clearance.
Lilly's (LLY) Taltz Gets Approval for Label Expansion in US
by Zacks Equity Research
Lilly (LLY) announced the label expansion of its psoriasis drug, Taltz, for the active psoriatic arthritis indication in the United States.
AbbVie Stock Up More Than 30% So Far in 2H17: Here's Why
by Zacks Equity Research
AbbVie's (ABBV) shares have gained 32.1% so far in the second half of the year supported by a series of positive news in the past few months.
The Zacks Analyst Blog Highlights: Amazon, AbbVie, Biogen, McCormick and Hyatt
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Amazon, AbbVie, Biogen, McCormick and Hyatt
J&J & Glaxo's Juluca Approval Puts Spotlight on HIV Space (Revised)
by Zacks Equity Research
As HIV and AIDS have limited medical cure but huge medical need, we see how different companies are trying to tap into this huge market.
Will New Drug Approvals Boost Novartis (NVS) Portfolio?
by Zacks Equity Research
Novartis (NVS) is facing stiff generic competition for key drugs. Nevertheless, we expect approval of new drugs to boost its portfolio.
Galapagos' CF Candidate Shows Potential in Phase II Study
by Zacks Equity Research
Galapagos' (GLPG) CFTR corrector candidate, GLPG2222, shows potential in a phase II study on CF patients.
Amgen (AMGN) Unveils Auto Injector Device for Enbrel in US
by Zacks Equity Research
Amgen launched its Enbrel Mini with AutoTouch, a new auto injector device for Enbrel in the United States.
Roche's (RHHBY) Hemophilia A Drug Receives FDA Approval
by Zacks Equity Research
Roche (RHHBY) hematology portfolio got a boost when the FDA approved Hemlibra (emicizumab-kxwh) for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adults and children with haemophilia A with factor VIII inhibitors.
Biotechs Trading Lower in Q4 on Macro Uncertainty, Tepid Q3
by Zacks Equity Research
After rising 15.4% in the first nine months of the year, the Medical-Biotech /Genetics industry has declined 13.4% so far in the fourth quarter.
Novartis (NVS) Arm's Biosimilars Study Results Encourage
by Zacks Equity Research
Novartis (NVS) generic arm, Sandoz, reported positive data from two phase III studies evaluating biosimilars of Humira and MabThera respectively.
Arena (ARNA) Completes Enrolment in Etrasimod Phase II Study
by Zacks Equity Research
Arena (ARNA) completed full enrollment with 157 patients in a phase II study evaluating etrasimod in ulcerative colitis (UC). Results from the study are expected in the first quarter of 2018.
Amgen Gets Positive CHMP Opinion to Expand Nplate's Label
by Zacks Equity Research
Amgen (AMGN) received positive CHMP opinion to expand Nplate's label to include pediatric patients and also for the marketing application of Avastin biosimilar.
The Zacks Analyst Blog Highlights: AbbVie, Union Pacific, Bristol-Myers, Weyerhaeuser and Colgate
by Zacks Equity Research
The Zacks Analyst Blog Highlights: AbbVie, Union Pacific, Bristol-Myers, Weyerhaeuser and Colgate
Biotech Stock Roundup: Celgene, Amgen, Gilead Hit by Q3 Results, Vertex Beats on All Fronts
by Arpita Dutt
It was all about earnings this week with major biotech companies like Gilead (GILD), Celgene and Amgen reporting third quarter results.
HCA Healthcare (HCA) Posts In-Line Q3 Earnings, Keeps View
by Zacks Equity Research
HCA Healthcare's (HCA) third quarter witnesses increase in revenues and admissions. However, expenses too escalate. The company reiterates guidance provided earlier this month.
AbbVie (ABBV) Q3 Earnings Top, Revenues In Line, View Up
by Zacks Equity Research
AbbVie's (ABBV) Q3 earnings surpass estimates with revenues matching the same. Sales of the company's lead marketed drug, Humira, also rise year over year.
Data and Earnings Deluge
by Zacks Equity Research
Data and Earnings Deluge
Q3 GDP Hits 3.0%, Q3 Earnings Take Pre-Market Higher
by Mark Vickery
We get a first look at Q3 GDP: 3.0%, up from the consensus estimate of 2.7%, and a second consecutive 3-handle following Q2???s final read of 3.1%.